Home > Division of Cancer RNA Research
Division of Cancer RNA Research
- Apr. 22, 2025
- A commentary written by Ryoichi Maezono has been published in the Journal of Cellular Immunology.
- Apr. 21, 2025
- The review article written by Masahiko Ajiro , titled -Aberrant RNA splicing regulation as a novel source of neoantigens- has been published in Japanese Journal of Cancer and Chemotherapy.
- Apr. 18, 2025
- Congrats to Ryoichi Maenosono―he has received the General Assembly Award at the 112th Annual Meeting of the Japanese Urological Association!!
- Apr. 15, 2025
- Congrats to Masahiko Ajiro ― his co–first-authored paper just came out in Science Advances!
- Apr. 1, 2025
- Akihide Yoshimi’s project titled 'Verification of drug discovery targeting cancer-specific cell surface receptors' has been selected for the AMED FY2025 Drug Discovery Booster.
- Apr. 1, 2025
- Akihide Yoshimi has been appointed as a Collaborative Professor at the Graduate School of Medicine, the University of Tokyo.
- Apr. 1, 2025
- Tomoya Muto's project has been accepted for a JSPS KAKENHI Grant-in-Aid for Scientific Research (B)!
- Apr. 1, 2025
- Asuka Kawachi's project has been accepted for a JSPS KAKENHI Grant-in-Aid for Scientific Research (C)!
- Apr. 1, 2025
- Parihe Muhetaer joined our team as a researcher!
- Apr. 1, 2025
- Kenshiro Nishihara joined our team as a researcher!

Our Research Interest
Our studies have been focused on how RNA processing including RNA splicing is altered in cancer and functionally drives cancer initiation and maintenance. The advent of high-throughput transcriptome sequencing has provided a wealth of information on RNA splicing on a genome-wide scale. It is now understood that > 95% of human genes are subject to alternative splicing. RNA splicing is considered to be a major mediator of proteome diversity through its ability to generate multiple transcripts with differing amino acid sequences from a single gene. The discovery of recurrent mutations in components of the RNA-splicing machinery in 2011 further highlighted the importance of aberrant splicing in cancer as well as a potential therapeutic vulnerability for cells bearing these mutations. Despite the major advances in our understanding of the genomics, molecular biology and therapeutic implications of altered RNA processing in cancer, the full contribution of aberrant RNA splicing to cancer pathogenesis has not been fully elucidated. Our aim is to contribute to the full understanding of the pathogenic roles of altered RNA processing in a variety of cancers and to the development of therapeutically efficacious and safe strategies to improve the outcome of cancer patients.

(Figure was made by using Wordle based on our recent papers)